RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $44
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $39 to $44.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and raises the price target from $39 to $44.